H.C. Wainwright initiated coverage of Crescent Biopharma (CBIO) with a Buy rating and $25 price target The company’s lead asset, CR-001, is a bispecific antibody targeting programmed cell death protein 1 and vascular endothelial growth factor, the analyst tells investors in a research note. The firm sees an attractive valuation at current share levels and views Crescent as a potential takeover target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CBIO: